SFAM
Springhill Fund Asset Management Portfolio holdings
AUM
$20.9M
1 Year Est. Return
–
AUM
$20.9M
AUM Growth
-$40.7M
(-66%)
Holding
30
Top Buys
| 1 | +$2.4M | |
| 2 | +$1.65M | |
| 3 | +$1.51M | |
| 4 |
Janux Therapeutics
JANX
|
+$1.32M |
| 5 |
Soleno Therapeutics
SLNO
|
+$1.29M |
Top Sells
| 1 | +$6.21M | |
| 2 | +$6.15M | |
| 3 | +$5.31M | |
| 4 |
AstraZeneca
AZN
|
+$5.01M |
| 5 |
Vera Therapeutics
VERA
|
+$4.63M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
26
Abivax
ABVX
$9.19B
| – | – |
-207,600
|
|
||
|
27
AstraZeneca
AZN
$293B
| – | – |
-76,500
|
|
||
|
BCYC
28
Bicycle Therapeutics
BCYC
$452M
| – | – |
-116,400
|
|
||
29
Cullinan Oncology
CGEM
$633M
| – | – |
-276,400
|
|
||
30
Cytokinetics
CYTK
$7.65B
| – | – |
-130,735
|
|